From the last conf call -------
Outlook for Third Quarter and Full Year 2013
The Company reaffirmed its previously communicated guidance for full year 2013, but increased the lower end of the range. 2013 full year revenue is forecasted to be in the range of $54 million to $60 million. The Company's goals for the third quarter of 2013 are for revenue to be in the range of $13.5 million to $16.0 million. The point within the range of revenue goals largely will be dependent on whether and how quickly the remaining MACs begin to reimburse for the Company's EpiFix® allografts.
Now if the company has guided over 16mill this quarter how might they achieve this?